Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Lower prostaglandin levels reduce pain signalling, lower fever by acting on the hypothalamus, and diminish inflammation at the site of injury.

The specific dose of Ibuprofen B. Braun is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Healthcare professionals follow local guidelines and product labeling to set the appropriate infusion rate and total amount.

Safety data for intravenous ibuprofen during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk, and a healthcare provider should evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other intravenous NSAIDs such as ketorolac, ibuprofen offers a similar analgesic and antipyretic profile but may have a slightly lower risk of renal toxicity at equivalent doses. Choice between agents depends on the clinical scenario, patient comorbidities, and institutional protocols.

Ibuprofen B. Braun should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer after removal from controlled storage.

The product is given by intravenous infusion under the supervision of qualified healthcare personnel. It is typically diluted in an appropriate compatible IV fluid and administered over a prescribed period, following aseptic technique and the infusion guidelines provided in the product’s prescribing information.

Serious risks include gastrointestinal bleeding, acute renal failure, hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke, especially in patients with pre‑existing risk factors. Prompt recognition and medical intervention are essential if any of these events occur.

Patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and those receiving certain anticoagulants without close monitoring should avoid using Ibuprofen B. Braun unless a clinician determines that benefits outweigh the risks.